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Abstract
Background—Galectin-3 (Gal-3) is a marker of myocardial fibrosis, and elevated levels are
associated with adverse outcomes. Mineralocorticoid receptor antagonists (MRA) modulate
cardiac fibrosis in HF patients, and have been shown to improve long term outcomes. We
examined whether treatment effects from MRA use differed by Gal-3 levels in ambulatory heart
failure patients enrolled in the HF-ACTION study.
Methods and Results—HF-ACTION was a randomized controlled trial of exercise training
versus usual care in patients with HF due to LV systolic dysfunction (NYHA Class II–IV, LVEF ≤
0.35, median follow-up 2.5 years). Galectin-3 was assessed at baseline in 895 patients. The
endpoint was all-cause mortality or all-cause hospitalization (ACM+ACH); all-cause mortality
(ACM) was a key secondary endpoint. A differential association of MRA use by increasing Gal3
concentration was tested using interaction terms in Cox proportional hazards models, adjusted for
covariates previously identified in this cohort, as well as age, sex, and race. Inverse Propensity
Weighted (IPW) methods were also used to assess this association. Approximately half the
patients were on an MRA (n=401). There was no significant interaction for the associations of
Gal-3 levels and MRA use on either endpoint (adjusted interaction p-value=0.76 for ACM+ACH;
p=0.26 for ACM). There was no evidence of improved outcomes for patients on an MRA
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compared to those not on MRA on either endpoint (HR=1.02, 95% CI [0.85–1.23], p=0.8;
HR=1.15, 95% CI [0.82–1.61], p=0.4, respectively). IPW analysis was consistent with the results
of the adjusted analysis.
Conclusion—Our study showed no evidence of interaction between Gal-3 and treatment effect
of MRA. Whether biomarkers may be used to predict which patients may benefit from an
mineralocorticoid receptor antagonist in HF requires further investigation.
Keywords
heart failure; biomarkers; galectin-3; mineralocorticoid receptor antagonists
Introduction
Galectin-3 (Gal-3) is a member of an evolutionarily conserved family of soluble β-
galactoside-binding lectins that play a key role in several diverse biological processes and
disease states.1 In the heart, galectin-3 is thought to augment fibrosis and modulate the
immune response, both pivotal processes in maladaptive cardiac remodeling. Studies have
also shown that elevated concentrations of galectin-3 provide important prognostic
information, particularly in patients with chronic heart failure.2–4
Aldosterone is a mineralocorticoid hormone that has been shown to play a pathophysiologic
role in cardiovascular remodeling through cardiac hypertrophy, fibrosis, and
inflammation.5, 6 Mineralocorticoid receptor antagonists modulate cardiac fibrosis in heart
failure patients, and have been shown to improve long term outcomes, reducing mortality by
up to 30% and readmission for heart failure by nearly 40%.7 Despite this, their uptake has
been slow in clinical practice, in part due to uncertainty about their effectiveness and safety
outside clinical trials.8, 9 It has been hypothesized that patients with elevated plasma levels
of Gal-3, indicating increased cardiac fibrosis, may be those who benefit most from
mineralocorticoid receptor antagonists.10, 11 A study by Calvier et al in rats showed that
cardiac fibrosis was mediated by Gal-3 and aldosterone activity, and that spironolactone
reversed the inflammatory and fibrotic response to aldosterone in the setting of elevated
Gal-3. Another study showed that in an experimental mouse model of cardiac
hyperaldosteronism, the MRA eplerenone reduced Gal-3 levels.6, 12 However, there have
been conflicting data. In a study by Weir et al, Gal-3 concentrations increased significantly,
by approximately 14% in patients treated with eplerenone.13 This study also indicated there
was no effect of eplerenone on remodeling, whether baseline galectin-3 levels were low or
high. Additionally, in the Controlled Rosuvastatin Multinational Trial in Heart Failure
(CORONA), higher Gal-3 levels were associated with current use of MRA’s.14 Thus, data
substantiating the hypothesis that elevated Gal-3 levels may predict beneficial outcomes on
MRA’s remain elusive.
To address this question, we examined whether the association between treatment effects
from MRA use and clinical outcomes differed by Gal-3 levels in patients enrolled in the HF-




The design, rationale, and primary results of the HF-ACTION study have been previously
published.15 Briefly, HF-ACTION was a randomized clinical trial evaluating the effect of
exercise training vs. usual care on long-term morbidity and mortality in patients with
chronic heart failure due to left ventricular systolic dysfunction (NYHA class II–IV, left
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ventricular ejection fraction (LVEF) < 0.35). The primary endpoint of HF-ACTION was a
composite of all-cause mortality and all-cause hospitalization over a median follow up of 2.5
years. Although not mandated, enrollment criteria included patients who were on optimal
heart failure therapy according to American College of Cardiology/American Heart
Association and Heart Failure Society of America guidelines.16, 17 An independent clinical
events committee adjudicated deaths and first cardiovascular hospitalizations. HF-ACTION
was approved by local Institutional Review Boards, and all patients provided written
informed consent.
Biomarker Assays
A sub-set of patients enrolled in the HF-ACTION study who agreed to participate in the
Biomarker substudy. Baseline blood samples were obtained on the same day as baseline
exercise testing but were obtained prior to exercise. Samples were collected via peripheral
vein into EDTA containing tubes, and then centrifuged immediately and stored at −70 C for
subsequent analysis. Galectin-3 levels were assessed on baseline samples using an enzyme-
linked immunosorbent assay (ELISA) developed by BG Medicine, Inc. in Waltham, MA,
USA, which quantitatively measures galectin-3 concentrations on plasma samples. The
assays were run at an academic core laboratory that was blinded to clinical data. The core
laboratory limit of quantification for Gal-3 measurement was unavailable, so values were
truncated at the 99th percentile of the observed distribution.
Statistical Analysis
Baseline characteristics were described according to use of MRA treatment and high vs low
Galectin-3 level at randomization. A Gal-3 cut-point of 17.8 ng/mL was used based on the
FDA approved labeling for use of the assay. A sensitivity analysis was also conducted using
the median split of Gal-3 levels in the HF ACTION cohort (14.01 ng/mL). Continuous
characteristics are described using medians and interquartile ranges, and compared across
the four combinations of MRA use and Gal-3 level using a Kruskal-Wallis test; categorical
characteristics are described by proportions and compared using the Pearson chi-square test
or exact test.
The primary endpoint was all-cause mortality or all-cause hospitalization; the key secondary
endpoint was all-cause mortality. Other secondary endpoints included cardiovascular (CV)
mortality or CV hospitalization, and CV mortality or HF hospitalization.
A differential association of MRA therapy by Gal-3 concentration was tested for each
endpoint using interaction terms in Cox proportional hazards models. To maximize power
and precision of our analyses, Gal-3 concentration was kept as a continuous variable in all
statistical models. For each endpoint, the regression analysis was adjusted for clinical risk
factors previously identified as HF-ACTION adjustment models. Adjustment models were
built using the approach described by O’Connor et al but with a larger set of candidate
variables.18 The clinical adjustment model for the primary endpoint included Weber class,
Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom stability, blood urea
nitrogen, region (USA versus non-USA), LVEF, sex, beta blocker dose, mitral regurgitation
(severe versus non-severe), and ventricular conduction. Adjustment covariates for the
secondary endpoints are described in the footnote to Table 2. Further, all models included
adjustment for age, sex, and race even when not present in the original HF-ACTION
adjustment model. Linearity assumptions were assessed for Gal-3; results suggested
truncation below 8 ng/mL and above the 25 ng/mL would provide an appropriate fit for each
outcome. Proportional hazards assumptions were checked for Gal-3 and MRA use; no
violation was suggested. The analysis plan specified that if the tested interaction was not
significant, an additive model (i.e. without the interaction term) would assess the
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relationship between MRA use and outcome adjusted for Gal-3 level and the previously
mentioned covariates. Direct adjusted survival curves were plotted for the primary and key
secondary endpoint for MRA use and for combinations of low vs. high Gal3 and MRA use.
Inverse Propensity Weighted (IPW) methods were also used to assess these interactions and
associations. A propensity model for MRA use included all covariates identified in any of
the HF-ACTION adjustment models previously described. Covariate balance was assessed
following appropriate methods19 and demonstrated adequate balance. Cox proportional
hazards models then assessed the association between MRA use and outcomes, weighted by
the inverse of the estimated probability of MRA treatment received. Statistical analysis was
performed by the Duke Clinical Research Institute using SAS software version 9.2 (SAS
Institute, Cary, NC) and p<0.05 was considered statistically significant.
Results
Evaluable baseline plasma samples were available for 895 patients, and baseline
characteristics for this study cohort stratified by MRA use (yes/no) and Gal-3 (high/low) are
shown in Table 1. Of the 895 patients, approximately half were on an MRA (n=401). The
median age of the study cohort was 59 years. There was no evidence to suggest a significant
difference in the median Gal-3 level in patients on MRA (13.8 [11.0 – 18.1] verses not on
MRA (14.2 [10.8 – 18.7].
There was no significant interaction for the associations of Gal-3 levels and MRA use on
either endpoint after adjusting for predictors of adverse outcomes in this cohort (adjusted
interaction p-value=0.76 for all-cause mortality + all-cause hospitalization; p=0.26 for all-
cause mortality). The association of MRA use with outcome was approximately the same
over the range of Gal-3 values (Figure 1-ACM+ACH; Figure 2-ACM). In adjusted
analysis, there was no evidence of improved outcomes for patients on an MRA compared to
those not on an MRA, on the primary endpoint (Figure 3) or mortality alone (Figure 4)
(HR=1.02, 95% CI [0.85–1.23], p=0.80; HR=1.15, 95% CI [0.82–1.61], p=0.43,
respectively). Inverse Propensity Weighted analysis was consistent with the results of the
adjusted analysis (Table 2). Results of the secondary endpoints of CV mortality/CV
hospitalization and CV mortality/HF hospitalization also showed no evidence of an
interaction (Table 2). Baseline characteristics and survival plots were also evaluated as a
sensitivity analysis using median Gal-3 levels (14.01 ng/mL), which yieldeding similar
results.
Discussion
Our study showed that there was no evidence of a differential association of MRA use with
outcomes by Gal3 level. Further, in this cohort, there was not a significant difference in
outcomes of patients on MRA after adjustment for important clinical variables.
Galectin-3 is a novel biomarker that has been shown to mediate fibrosis in the failing
heart.20 Studies have shown that Gal-3 can be used to predict adverse outcomes in patients
with chronic heart failure, with those with elevated levels having a higher risk of adverse
outcomes, including mortality or hospitalization.18, 21–23 Data from the CORONA trial
suggested that lower Gal-3 levels may confer a benefit with rosuvastatin therapy.14
Additionally, this study showed that MRA use was associated with higher levels of Gal-3. It
has been suggested, however, that this may be related to the antifibrotic effects of MRA’s
which may trigger feedback upregulation of Gal-3. It is also unclear whether galectin-3 may
be rising in response to MRA induced renal dysfunction.24
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Another possible explanation for our findings may be related to the timing of Gal-3
measurements and use of MRA’s. Galectin-3 levels are not affected by decompensation, and
generally remain stable over time.25 Therefore, it may be plausible that by the time the
biomarker is elevated, it is too late to observe the benefit in patients who receive MRA’s.
We previously demonstrated that in HF-ACTION, after multivariable adjustment for a large
number of clinical variables including NT-proBNP, galectin-3 was no longer a significant
predictor of any cardiovascular outcomes examined in our study.2 In the context of this
finding, whether treatment decisions could be determined with Gal-3 levels would be
valuable. Mineralocorticoid receptor antagonists have been shown to significantly improve
long term outcomes in patients with systolic heart failure.26–28 Their mechanism of action
includes modulating cardiac fibrosis in these patients.29 However, findings from large
registries have demonstrated conflicting results. While some have shown a benefit, others
have failed to note this in clinical practice.8, 30, 31 For example, a recent study using clinical
registry data linked to Medicare claims from 2005 – 2010, there was no benefit observed in
treated versus untreated patients on the endpoints of mortality (p=0.62), or for
cardiovascular readmissions (p=0.65). However, there was a significant reduction in
hospitalizations for heart failure in patients treated with an MRA (p<0.001).8 Similarly, in
our cohort, there was no evidence of improved outcomes for patients treated with MRA’s
compared to those not on an MRA on the endpoint of all-cause mortality + all-cause
hospitalization, or the endpoint of all-cause mortality alone.
A number of possibilities may explain differences in our findings from those of previous
randomized, controlled trials. Prospective, randomized trials testing the benefit of MRA’s
have a pre-specified patient population, rigorous follow-up, and measures to enforce
adherence. Because HF-ACTION was not designed to test the effects of MRA’s, the setting
of MRA use was more similar to the registries, where patients are treated based on clinical
use. In addition, important differences exist between the study populations. Patients in HF
ACTION were slightly younger than those in the EMPHASIS trial, with a lower SBP and
slightly lower LVEF. Patients in HF ACTION also had a higher use of ICD’s and
biventricular pacemakers than the cohorts of the mineralocorticoid receptor antagonist trials,
which may further complicate the benefit that may be achieved by mineralocorticoid
receptor antagonists. In addition, only 3% of the EMPHASIS cohort was made up of black
patients, yet they comprised 31% of the HF ACTION cohort. A small number of studies
have indicated that there may be racial differences in aldosterone concentrations and K+
response to aldosterone blockade with spironolactone. However the mechanisms for these
findings have not been clearly identified and a racial difference in response to these agents
has not been confirmed.32, 33
Our findings could be confounded by several important limitations. This was a retrospective
analysis, and although we adjusted for known predictors of adverse outcome, the possibility
of important unidentified prognostic indicators must be considered. In addition, the timing,
dose, and type of mineralocorticoid receptor antagonists in each group were not known,
which may play a role in the benefits observed in prospective trials.28 Further, the trial
inclusion/exclusion criteria may limit generalizability of these findings. Gal-3 was only
collected on a subsample of the original trial leaving a limited available sample size; a
power calculation for this biomarker analysis was not done a priori. In our study, the overall
effect of MRA therapy was neutral. Whether Gal-3 may be useful in trials where MRA
therapy is successful cannot be determined by this study. However, using a biomarker to
determine which patients may benefit in the context of a neutral effect of therapy in a
general cohort is perhaps the most valuable potential of these markers.
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In a retrospective analysis of a large well-treated cohort of ambulatory patients with systolic
heart failure, there was no evidence of a differential association between Galectin-3 levels
and mineralocorticoid receptor antagonist and clinical outcomes. Whether biomarkers may
be used to predict which patients may benefit from an MRA in HF requires further
investigation in a prospective, randomized clinical trial.
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Adjusted estimated event rate for all-cause mortality or all-cause hospitalization by Gal-3
and MRA use.
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Adjusted estimated event rate for all-cause mortality by Gal-3 and MRA use.
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Adjusted estimated event rate for all-cause mortality or all-cause hospitalization by MRA
use.
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Adjusted estimated event rate for all-cause mortality by MRA use.
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Table 2
Mineralocorticoid receptor antagonist Use, Interaction with Gal-3, and Clinical Outcomes
Model Association between MRA use and Outcome without
Interaction with Gal-3











1.02 (0.85, 1.23) 1.02 (0.84, 1.23) 0.76 0.94
All-cause mortality [adjusted2
n=771]
1.15 (0.82, 1.61) 1.05 (0.72, 1.53) 0.26 0.45
Cardiovascular (CV) mortality
or CV hospitalization [adjusted3
n=699]
0.97 (0.79, 1.18) 1.01 (0.82, 1.25) 0.52 0.56
CV mortality or heart failure
(HF) hospitalization [adjusted4
n=686]
0.94 (0.72, 1.23) 0.96 (0.73, 1.25) 0.40 0.97
*
IPW n=674 for all outcomes
1
Adjusted for age, race (black vs white vs other), galectin-3, and the following HF-ACTION adjustment model covariates: sex, peak VO2
characterized by Weber class, KCCQ symptom stability score, blood urea nitrogen, county (US vs non-US), LVEF, beta blocker dosage, mitral
regurgitation grade, and ventricular conduction on the baseline CPX test
2
Adjusted for age, race (black vs white vs other), galectin-3, and the following HF-ACTION adjustment model covariates: sex, exercise duration
on the baseline CPX test, serum creatinine level, BMI, loop diuretic dosage, LVEF, CCS angina classification, and ventricular conduction on the
baseline CPX test
3
Adjusted for age, galectin-3, and the following HF-ACTION adjustment model covariates: sex, race (black vs white vs other), LVEF, mitral
regurgitation grade, ventricular conduction on the baseline CPX test, KCCQ symptom stability score, blood urea nitrogen, heart rate at peak
exercise on the baseline CPX test, nitrate use, peak VO2 characterized by Weber class, and KCCQ total symptom score
4
Adjusted for galectin-3 and the following HF-ACTION adjustment model covariates: age, sex, race (black vs white vs other), loop diuretic
dosage, LVEF, mitral regurgitation grade, ventricular conduction on the baseline CPX test, KCCQ symptom stability score, blood urea nitrogen,
peak VO2 characterized by Weber class, and VE/VCO2 slope
5
IPW models used the following covariates in the propensity model: age, sex, race (black vs white vs other), galectin-3, peak VO2 characterized by
Weber class, KCCQ symptom stability score, blood urea nitrogen, county (US vs non-US), LVEF, beta blocker dosage, mitral regurgitation grade,
ventricular conduction on the baseline CPX test, CCS angina classification, exercise duration on the baseline CPX test, serum creatinine level,
BMI, loop diuretic dosage, heart rate at peak exercise on the baseline CPX test, nitrate use, KCCQ total symptom score, and VE/VCO2 slope
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